

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 July 2005 (07.07.2005)

PCT

(10) International Publication Number
WO 2005/060457 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2004/037600

(22) International Filing Date:
10 November 2004 (10.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/527,882 4 December 2003 (04.12.2003) US
PCT/US2004/014507 7 May 2004 (07.05.2004) US

(71) Applicant (for all designated States except US): **PRO-TEIN DESIGN LABS, INC.** [US/US]; 34801 Campus Drive, Fremont, CA 94555 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BALASA, Balaji** [US/US]; 4498 Jasmine Court, Union City, CA 94587 (US). **TSURUSHITA, Naoya** [JP/US]; 3719 Redwood

Circle, Palo Alto, CA 94306 (US). **LANDOLFI, Nicolas, F.** [US/US]; 240 Gloria Circle, Palo Alto, CA 94306 (US).

(74) Agent: **CHIANG, Robin, C.**; Howrey Simon Arnold & White, LLP, 2941 Fairview Park Drive, Box 7, Falls Church, VA 22042 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH ANTI-IP-10 ANTIBODIES

[A] VH

			<u>CDR1</u>	40
HuAIP12	EVQLVQSGAE	VKKPGATVKI	SCKVSGYTFT	DYSMHWVRQA
HuAIP13	EVQLVQSGAE	VKKPGATVKI	SCKVSGYTFT	DYSMHWVRQA
T55I	EVQLVQSGAE	VKKPGATVKI	SCKVSGYTFT	DYSMHWVRQA
G104A	EVQLVQSGAE	VKKPGATVKI	SCKVSGYTFT	DYSMHWVRQA

			<u>CDR2</u>	80
HuAIP12	PGKGLKWMGW	INTETGEPTY	ADDFKGRFTF	TLDTSTSTAY
HuAIP13	PGKGLKWMGW	INTETGEPTY	ADDFKGRFTF	TLDTSTSTAY
T55I	PGKGLKWMGW	INTETGEPTY	ADDFKGRFTF	TLDTSTSTAY
G104A	PGKGLKWMGW	INTETGEPTY	ADDFKGRFTF	TLDTSTSTAY

			<u>CDR3</u>	119
HuAIP12	MELSSLRSED	TAVYYCARNY	DYDGYFDVWG	QGTTTVVSS
HuAIP13	MELSSLRSED	TAVYYCARNY	DYDGYFDVWG	QGTTTVVSS
T55I	MELSSLRSED	TAVYYCARNY	DYDGYFDVWG	QGTTTVVSS
G104A	MELSSLRSED	TAVYYCARNY	DYDGYFDVWG	QGTTTVVSS

[B] VL

			<u>CDR1</u>	40
HuAIP12	DIQMTQSPSS	LSASVGDRVT	ITCKASQDIN	KYLAWYQQKP
HuAIP13	DIQMTQSPSS	LSASVGDRVT	ITCKASQDIN	KYLAWYQQKP

			<u>CDR2</u>	80
HuAIP12	GKAPKLLIHY	TSTLQPGIPS	RFGSGSGGRD	YTFTISSLPQ
HuAIP13	GKAPKLLIHY	TSTLQPGIPS	RFGSGSGGRD	YTFTISSLPQ

			<u>CDR3</u>	107
HuAIP12	EDIATYYCLO	YDNLFTPGQ	GTKLEIK	
HuAIP13	EDIATYYCLO	YDNLFTPGQ	GTKLEIK	

Alignment of the VH (A) and VL (B) amino acid sequences of HuAIP12, its derivatives (in A), and HuAIP13. The amino acid sequences of the mature VH and VL regions are shown in single letter code. Amino acids that differ from the counterparts in the HuAIP12 VH or VL are bold and double-underlined.

(57) Abstract: The present invention is directed to high affinity anti-human IP-10 antibodies or antigen-binding fragments of these antibodies, including chimeric, humanized or fully human antibodies. The present invention is also directed to a method of reducing the severity of at least one symptom of an inflammatory bowel disease in a subject in need thereof comprising administering to said subject an effective amount of an antagonist of IP-10, including the antibodies or antibody fragments of the present invention.



European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*